Form 4 Tracker
Philip Astley-Sparke

Director · 4 filings · Latest: Jun 16, 2026

enGene Therapeutics Inc.
Replimune Group, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
REPL
Philip Astley-SparkeDirectorMay 18, 2026
Sale
$5.0817,657$89.7K1,412,414